Published • loading... • Updated
InflaRx seeks to fill void left by Amgen’s Tavneos in Europe - European Biotechnology Magazine
Summary by European-biotechnology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
InflaRx seeks to fill void left by Amgen’s Tavneos in Europe - European Biotechnology Magazine
InflaRx is preparing for discussions with regulators in Europe over two drugs that could provide an alternative to patients treated with Amgen’s Tavneos (avacopan), which is set to be removed from the EU market for the rare blood vessel inflammation disease ANCA-associated vasculitis (AAV). The post InflaRx seeks to fill void left by Amgen’s Tavneos in Europe appeared first on European Biotechnology Magazine.
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
